The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 2829-2841

  Moran, Gary ^a   Sullivan, Derek ^a   Morschhäuser, Joachim ^a   Coleman, David ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MESSENGER RNA; TYROSINE;

ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA DUBLINIENSIS; FUNGAL GENE; FUNGUS ISOLATION; GENE SEQUENCE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; NONSENSE MUTATION; OPEN READING FRAME; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STOP CODON; WESTERN BLOTTING;

EID: 0036720765     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.2829-2841.2002     Document Type: Article

References (35)

1. Strain variation among and antifungal susceptibilities of isolates of Candida krusei
2. Candida dubliniensis candidaemia in an HIV-positive patient in Ireland
3. Candida dubliniensis fungemia: The first four cases in North America
4. Candidiasis: The emergence of a novel species, Candida dubliniensis
5. A common drug-responsive element mediates the upregulation of the Candida albicans ABC-transporters CDR1 and CDR2, two genes involved in antifungal drug resistance
6. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains
7. Reduced azole susceptibility of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation
8. Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo
9. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis
10. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates
11. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
12. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation
13. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis
14. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro
15. The construction and use of cDNA libraries for genetic selections
16. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients
17. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
18. Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel
19. Molecular cloning and characterisation of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals
20. Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in patients with AIDS
21. Epidemiology of oral candidiasis in HIV-infected patients: Colonisation, infection, treatment, and emergence of fluconazole-resistance
22. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents
23. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterisation of CDR2, a new multidrug ABC transporter gene
24. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
25. Differential activation of a Candida albicans virulence gene family during infection
26. Isogenic strain construction and gene targeting in Candida dubliniensis
27. Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients
28. Candida dubliniensis: Characteristics and identification
29. Candida dubliniensis sp. nov: Phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals
30. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
31. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
32. Three distinct secreted aspartyl proteinases in Candida albicans
33. Targeted gene disruption in Candida albicans wild-type strains: The role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates
34. MDR1-mediated drug resistance in Candida dubliniensis